Smith & Nephew plc vs Target Corporation — how do they compare? Smith & Nephew plc trades at $27.67 (market cap $11.63B), while Target Corporation trades at $158 (market cap $73.92B). The key difference: Target Corporation is far larger — about 6.4× Smith & Nephew plc's market cap, and Target Corporation is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| SNN | TGT | |
|---|---|---|
Market Cap | $11.63B | $73.92B |
Sector | Health | Consumer Cyclical |
52-Week High | $38.53 | $169.90 |
52-Week Low | $27.80 | $83.68 |
Enterprise Value | $14.66B | $87.20B |
Dividend Yield | 2.85% | 2.85% |
Signals from Pluang's Aura AI — not financial advice
Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.
Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.
Target Corporation (TGT) trades at $162.71, down 1.05% on the day, with strong technical momentum and solid fundamentals. The stock shows bullish moving average signals and has consistently beaten earnings estimates in recent quarters. Revenue remains stable around $107 billion with improving profitability margins. Recent news highlights CEO Michael Fiddelke's successful turnaround strategy and the company's expanding non-merchandise revenue streams.
Target presents a balanced investment case with fair valuation metrics and strong dividend history, though competitive retail pressures and valuation expansion pose risks. Analyst consensus leans slightly bullish with a $166.67 price target, representing modest upside potential from current levels. The company's operational efficiency improvements and digital growth initiatives support continued earnings momentum.
Trailing returns across standard periods
Latest headlines on both assets
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →